Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report

Abstract Background Avelumab is an anti-programmed cell death ligand 1 (PD-L1) antibody approved for treatment of Merkel cell carcinoma (MCC) and locally advanced or metastatic urothelial carcinoma. It shares a similar side effect profile to other immune checkpoint inhibitors, including immune-relat...

Full description

Bibliographic Details
Main Authors: Michael A. Cardis, Hong Jiang, Julius Strauss, James L. Gulley, Isaac Brownell
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Merkel cell
Immunology
Lichen planus-like keratosis
Immune checkpoint
Drug reactions
Online Access:http://link.springer.com/article/10.1186/s12885-019-5759-1

Internet

http://link.springer.com/article/10.1186/s12885-019-5759-1

Similar Items